miR-21 expression predicts prognosis in hepatocellular carcinoma - 20/11/14
, Hong-Fei Zhang, Lei Wang, Yan-Peng Ma, Fei Gao, Shao-Jun Zhang, Li-Chao WangBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Purpose |
The aim was to investigate the expression level of miR-21 in HCC tissues and its prognostic value among Asian population.
Methods |
In the present study, expression of miR-21 was evaluated by qRT- PCR in tumor and adjacent non-neoplastic tissues in 119 HCC patients. The association of miR-21 expression with clinicopathological factors and the prognosis of HCC patients was also analyzed. Survival analysis was performed using the Kaplan-Meier method and Cox's proportional hazards model.
Results |
We found that miR-21 expression was significantly higher in HCC tissues compared with normal adjacent liver tissues (P<0.0001). The 5-year overall survival (OS) of high miR-21 expression group was significantly shorter than that of low miR-21 expression group (40.2% vs. 70.7%; P=0.007). Moreover, the 5-year disease-free survival (DFS) of high miR-21 expression group was also significantly shorter than that of low miR-21 expression group (17.4% vs. 57.3%; P=0.001). Furthermore, in a multivariate Cox model, we found that miR-21 expression was an independent poor prognostic factor for both 5-year OS (hazards ratio [HR]=3.189, 95% confidence interval [CI]=1.911–10.012, P=0.03) and 5-year DFS (HR=5.897, CI=3.009–13.763, P<0.001) in HCC.
Conclusions |
The results of the present study suggested miR-21 expression level could be a novel potential biomarker for HCC prognosis.
Le texte complet de cet article est disponible en PDF.Plan
Vol 38 - N° 6
P. 715-719 - décembre 2014 Retour au numéro
Article précédent
- Comparison osteopontin vs AFP for the diagnosis of HCC: A meta-analysis
- Hao-Guang Wan, Hao Xu, Yu-Ming Gu, Hui Wang, Wei Xu, Mao-Heng Zu
- Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: A prospective multicenter cohort
- Philippe Halfon, Denis Ouzan, Tarik Asselah, Christophe Renou, Thierry Allègre, Patrick Delasalle, Alain Lafeuillade, Jean-François Cadranel, Nabil Haddad, Hacène Khiri, Guillaume Pénaranda, Marc Bourlière, Iliade Investigators 1
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?